162 related articles for article (PubMed ID: 28926323)
1. [Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.].
Sousa DC; Leal I; Costa J; Vaz-Carneiro A
Acta Med Port; 2017 Aug; 30(7-8):513-516. PubMed ID: 28926323
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2011 May; (5):CD008214. PubMed ID: 21563165
[TBL] [Abstract][Full Text] [Related]
4. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage.
Cheema RA; Mushtaq J; Al-Khars W; Al-Askar E; Cheema MA
Retina; 2010; 30(10):1646-50. PubMed ID: 20634777
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
6. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.
Modarres M; Nazari H; Falavarjani KG; Naseripour M; Hashemi M; Parvaresh MM
Eur J Ophthalmol; 2009; 19(5):848-52. PubMed ID: 19787608
[TBL] [Abstract][Full Text] [Related]
8. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
Sato T; Morita S; Bando H; Sato S; Ikeda T; Emi K
Middle East Afr J Ophthalmol; 2013; 20(1):51-5. PubMed ID: 23580852
[TBL] [Abstract][Full Text] [Related]
9. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy.
Yang CM; Yeh PT; Yang CH
Ophthalmology; 2007 Apr; 114(4):710-5. PubMed ID: 17275908
[TBL] [Abstract][Full Text] [Related]
11. The role of intraoperative bevacizumab for prevention of postoperative vitreous hemorrhage in diabetic vitreous hemorrhage.
Göncü T; Özdek S; Ünlü M
Eur J Ophthalmol; 2014; 24(1):88-93. PubMed ID: 23787453
[TBL] [Abstract][Full Text] [Related]
12. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment.
Yeung L; Liu L; Wu WC; Kuo YH; Chao AN; Chen KJ; Yang KJ; Chen TL; Lai CC
Acta Ophthalmol; 2010 Sep; 88(6):635-40. PubMed ID: 19432872
[TBL] [Abstract][Full Text] [Related]
13. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
Ahn J; Woo SJ; Chung H; Park KH
Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy.
Yang CM; Yeh PT; Yang CH; Chen MS
Am J Ophthalmol; 2008 Aug; 146(2):211-217. PubMed ID: 18547539
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
Jiang T; Gu J; Zhang P; Chen W; Chang Q
BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
[TBL] [Abstract][Full Text] [Related]
16. PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Wakabayashi Y; Usui Y; Tsubota K; Ueda S; Umazume K; Muramatsu D; Goto H
Retina; 2017 Dec; 37(12):2317-2325. PubMed ID: 28098727
[TBL] [Abstract][Full Text] [Related]
17. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
Simunovic MP; Maberley DA
Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
[TBL] [Abstract][Full Text] [Related]
18. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab at the end of diabetic vitrectomy for prevention of postoperative vitreous hemorrhage: a comparative study.
Jirawison C; Ittipunkul N
J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S136-42. PubMed ID: 22696866
[TBL] [Abstract][Full Text] [Related]
20. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.
Zhang ZH; Liu HY; Hernandez-Da Mota SE; Romano MR; Falavarjani KG; Ahmadieh H; Xu X; Liu K
Am J Ophthalmol; 2013 Jul; 156(1):106-115.e2. PubMed ID: 23791371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
